^
No biomarker
GBM
Krabeva (bevacizumab biosimilar)
Sensitive
:
A1
Biocon Press Release - 2wk
TNFA overexpression
GBM
bevacizumab
Resistant
:
C3
Acta Neuropathol Commun - 3wk
No biomarker
GBM
Byvasda (bevacizumab biosimilar)
Sensitive
:
A1
No biomarker
GBM
bevacizumab
Sensitive
:
A1
No biomarker
GBM
temozolomide
Sensitive
:
A1
No biomarker
GBM
carmustine
Sensitive
:
A1
No biomarker
GBM
Zirabev (bevacizumab biosimilar)
Sensitive
:
A1
No biomarker
GBM
Mvasi (bevacizumab biosimilar)
Sensitive
:
A1
No biomarker
GBM
PCV
Sensitive
:
A2
MGMT promoter methylation
GBM
temozolomide
Sensitive
:
A2
No biomarker
GBM
lomustine
Sensitive
:
A2
No biomarker
GBM
regorafenib
Sensitive
:
A2
No biomarker
GBM
VAL-083
Sensitive
:
B
No biomarker
GBM
enzastaurin
Sensitive
:
B
No biomarker
GBM
DNX-2401
Sensitive
:
B
No biomarker
GBM
GDC-0084
Sensitive
:
B
MGMT unmethylation
GBM
temozolomide
Sensitive
:
B
No biomarker
GBM
GLR2007
Sensitive
:
B
No biomarker
GBM
VB-111
Sensitive
:
B
No biomarker
GBM
CYNK-001
Sensitive
:
B
BRAF V600E
GBM
trametinib + dabrafenib
Sensitive
:
C1
BRAF V600E
GBM
vemurafenib
Sensitive
:
C1
MSI-H/dMMR
GBM
nivolumab
Sensitive
:
C1
BRAF V600
GBM
vemurafenib
Sensitive
:
C1
BRAF V600E
GBM
dabrafenib
Sensitive
:
C1
EGFR mutation
GBM
erlotinib
Sensitive
:
C1
VERI is free for non-commercial use, no login needed.
Content on this site is for research purposes only and is not intended  to be a substitute for medical advice.
For commercial access, including additional premium features, please contact us.
By using VERI, you are agreeing to our